Editas Medicine Inc Cash Flow Conversion Efficiency
Editas Medicine Inc cash flow conversion efficiency. Based on the latest financial reports, Editas Medicine Inc (EDIT) has a cash flow conversion efficiency ratio of -0.281x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.57 Million) by net assets ($105.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Editas Medicine Inc (2013–2025)
Cash flow conversion efficiency of Editas Medicine Inc from 2013 to 2025. This chart illustrates how Editas Medicine Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Editas Medicine Inc share price for real-time trading data and today's change.
Editas Medicine Inc Cash Flow Conversion Ratio Explained
Editas Medicine Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Editas Medicine Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Editas Medicine Inc ranked by their cash flow conversion efficiency. Also see EDIT stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Spear REIT Ltd
JSE:SEA
|
0.045x |
|
VST Industries Limited
NSE:VSTIND
|
0.048x |
|
Hefei Kewell Power System Co Ltd
SHG:688551
|
0.001x |
|
SNDL Inc.
NASDAQ:SNDL
|
0.029x |
|
Shihlin Paper Corp
TW:1903
|
-0.002x |
|
Shanghai Kai Kai Industry Co Ltd A
SHG:600272
|
0.021x |
|
Agro Tech Foods Limited
NSE:ATFL
|
0.022x |
|
Sarkuysan Elektrolitik Bakir Sanayi ve Ticaret AS
IS:SARKY
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Editas Medicine Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Editas Medicine Inc from 2013 to 2025. Review EDIT free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.29 Million | $-165.24 Million | -6.055x | -286.66% |
| 2024-12-31 | $134.27 Million | $-210.28 Million | -1.566x | -313.62% |
| 2023-12-31 | $349.10 Million | $-132.18 Million | -0.379x | +23.00% |
| 2022-12-31 | $360.68 Million | $-177.35 Million | -0.492x | -66.19% |
| 2021-12-31 | $553.64 Million | $-163.80 Million | -0.296x | +35.25% |
| 2020-12-31 | $393.59 Million | $-179.84 Million | -0.457x | -194.86% |
| 2019-12-31 | $262.44 Million | $-40.67 Million | -0.155x | +19.93% |
| 2018-12-31 | $236.16 Million | $-45.71 Million | -0.194x | -327.65% |
| 2017-12-31 | $208.08 Million | $-9.42 Million | -0.045x | +87.80% |
| 2016-12-31 | $134.61 Million | $-49.93 Million | -0.371x | -670.56% |
| 2015-12-31 | $-83.11 Million | $-5.40 Million | 0.065x | -88.51% |
| 2014-12-31 | $-15.29 Million | $-8.65 Million | 0.566x | -64.16% |
| 2013-12-31 | $-1.76 Million | $-2.78 Million | 1.579x | -- |
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The… Read more